tbuckley/cabot-search huggingface dataset:
Leukocyte-Expressed β <sub>2</sub> -Adrenergic Receptors Are Essential for Survival After Acute Myocardial Injury
Authors: Laurel A. Grisanti, Anna M. Gumpert, Christopher J. Traynham, Joshua E. Gorsky, Ashley A. Repas, Erhe Gao, Rhonda L. Carter, Daohai Yu, John W. Calvert, Andrés Pun García, Borja Ibáñez, Joseph E. Rabinowitz, Walter J. Koch, Douglas G. Tilley
Journal: Circulation (2016)

Background: Immune cell–mediated inflammation is an essential process for mounting a repair response after myocardial infarction (MI). The sympathetic nervous system is known to regulate immune system function through β-adrenergic receptors (βARs); however, their role in regulating immune cell responses to acute cardiac injury is unknown. Methods: Wild-type (WT) mice were irradiated followed by isoform-specific βAR knockout (βARKO) or WT bone-marrow transplantation (BMT) and after full reconstitution underwent MI surgery. Survival was monitored over time, and alterations in immune cell infiltration after MI were examined through immunohistochemistry. Alterations in splenic function were identified through the investigation of altered adhesion receptor expression. Results: β 2 ARKO BMT mice displayed 100% mortality resulting from cardiac rupture within 12 days after MI compared with ≈20% mortality in WT BMT mice. β 2 ARKO BMT mice displayed severely reduced post-MI cardiac infiltration of leukocytes with reciprocally enhanced splenic retention of the same immune cell populations. Splenic retention of the leukocytes was associated with an increase in vascular cell adhesion molecule-1 expression, which itself was regulated via β-arrestin–dependent β 2 AR signaling. Furthermore, vascular cell adhesion molecule-1 expression in both mouse and human macrophages was sensitive to β 2 AR activity, and spleens from human tissue donors treated with β-blocker showed enhanced vascular cell adhesion molecule-1 expression. The impairments in splenic retention and cardiac infiltration of leukocytes after MI were restored to WT levels via lentiviral-mediated re-expression of β 2 AR in β 2 ARKO bone marrow before transplantation, which also resulted in post-MI survival rates comparable to those in WT BMT mice. Conclusions: Immune cell–expressed β 2 AR plays an essential role in regulating the early inflammatory repair response to acute myocardial injury by facilitating cardiac leukocyte infiltration.
&lt;TITLE&gt;Hypertensive Kidney Disease&lt;/TITLE&gt;
Authors: Janet Torpy, Cassio Lynm, Richard M Glass
Journal: JAMA (2002)

Hypertensive Kidney DiseaseH ypertension (high blood pressure) causes problems for many organs in the body, including the kidneys.Kidney problems caused by high blood pressure (hypertensive kidney disease) occur often in persons who have undetected, untreated, or poorly controlled hypertension.Kidney problems are also called renal dysfunction or renal failure.Certain groups of people, including African Americans and Native Americans, are more at risk for having hypertensive kidney disease.High blood pressure is the second leading cause of kidney failure, surpassed only by diabetes.African Americans are 6 times more likely than whites to have chronic renal failure related to high blood pressure.The November 20, 2002, issue of JAMA includes an article about high blood pressure and its effect on the kidneys.
Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML)
Authors: Jolieke G van Oosterwijk, Eric I Zimmerman, Yong-Dong Wang, Shelley Orwick, Aksana Vasilyeva, Katja Schuster, Abhijit Ramachandran, Hiroto Inaba, Sharyn D Baker
Journal: Blood (2014)
Tissue Engineering: Mechanocompatible Polymer-Extracellular-Matrix Composites for Vascular Tissue Engineering (Adv. Healthcare Mater. 13/2016)
Authors: Bin Jiang, Rachel Suen, Jiao-Jing Wang, Zheng J. Zhang, Jason A. Wertheim, Guillermo A. Ameer
Journal: Advanced Healthcare Materials (2016)

Heparinized mechanocompatible polymer-extracellular matrix (ECM) composites to improve vascular graft performance are presented by J. A. Wertheim, G. A. Ameer, and co-workers on page 1594. Polymer-coated ECM is visualized by the purple color. The composite vascular graft reduced intimal hyperplasia in a rodent model, revealed by α-smooth muscle actin staining (green). The method shows promise for tissue engineering where immobilization of bioactive molecules is desirable.
PD-006 Final analysis of stage 1 data from a randomized phase 2 study of PEGPH20 plus nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients, utilizing Ventana companion diagnostic assay
Authors: S. Hingorani, A. Bullock, W. Harris, W. Wu, P. Jiang, D. Chondros, S. Khelifa, C. Aldrich, J. Pu, A. Hendifar
Journal: Annals of Oncology (2016)
Body Awareness Group Therapy for Patients with Personality Disorders
Authors: Svein Friis, Ulla-Britt Skatteboe, Magnhild Kvamsdal Hope, Per Vaglum
Journal: Psychotherapy and Psychosomatics (1989)

The Body Awareness Rating Scale (BARS) was developed to evaluate the treatment process of the Body Awareness Group Therapy. The BARS subscales proved to have high interrater reliability. A factor analysis revealed two factors which seemed to measure one awareness and one movement dimension. The BARS was sensitive to change. As hypothesized, the BARS improvement enlarged with increasing duration of treatment. At discharge the good BARS outcome patients had improved significantly more than the poor BARS outcome ones, both concerning symptoms and global psychopathology.
Ultrasonography-triggered diagnosis of putrid, ulcero-phlegmonous, hemorrhagic appendicitis and periappendicitis with an atypical symptom pattern: a case report
Authors: Hagen Frickmann, Sven A. Jungblut
Journal: Military Medical Research (2016)

Asymptomatic and oligosymptomatic appendicitis are rare and challenging diagnoses that should not be missed.A young female patient presented with mild to moderate pain in the middle and lower abdomen, and the results of physical examination, including digital rectal examination, were otherwise non-contributory. Ultrasonography demonstrated a marked increase of the outer appendiceal diameter up to 12 mm and a trace of free liquid around the terminal ileum. Subsequent surgical exploration and histological examination allowed for a final diagnosis of putrid, ulcero-phlegmonous, hemorrhagic appendicitis and periappendicitis.Ultrasonography is increasingly used for the diagnosis of appendiceal inflammation, particularly in military medical settings. Increases in the outer appendiceal diameter up to >6 mm under compression have recently been demonstrated to be indicative of acute appendicitis. At a minimum, in cases with doubtful physical examination results, ultrasonography should be considered as an element in the diagnosis of acute appendicitis.
FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen.
Authors: Nathan Hale Fowler, Joseph Pearlberg, Les H. Brail, Weiliang Shi, Liewen Jiang, Carrie Condon, Mathias J. Rummel
Journal: Journal of Clinical Oncology (2016)

TPS7578 Background: Most patients with follicular lymphoma (FL) experience a durable response after initial chemotherapy, however approximately 20% relapse within 24 months of initial treatment. These chemo-refractory FL patients have a significantly shorter survival despite additional lines of chemotherapy (Casulo et al. J Clin Oncol. 2015; 33:2516). Inhibitors of phosphoinositide-3-kinase (PI3K) may offer an alternative to chemotherapy for these early relapsed patients. Duvelisib (IPI-145), an oral, dual inhibitor of PI3K-δ and PI3K-γ is being developed for the treatment of hematologic malignancies, including FL. In a Phase 1 study that included patients with FL, duvelisib in combination with rituximab was well tolerated and showed some preliminary efficacy (Flinn I et al. Poster 3928, ASH meeting 2015), suggesting further study was warranted. Methods: FRESCO is a Phase 2, randomized study to evaluate the efficacy, safety, and pharmacokinetics (PK) of duvelisib plus rituximab (DR) vs R-CHOP in patients with relapsed/refractory FL (NCT02605694). This global study will enroll approximately 230 adult patients with FL who have progressed within 24 months of initiating an alkylator-based chemotherapy regimen. Patients must have previously received rituximab, but must not have received prior R-CHOP. Up to two prior lines of therapy are allowed. Patients will be randomized 1:1 to either DR or R-CHOP. Patients randomized to DR will receive duvelisib 25 mg BID continuously in combination with rituximab 375 mg/m2 IV on Day 1 of Cycles 1-6. Patients will receive duvelisib until disease progression or unacceptable toxicity. Patients randomized to R-CHOP will receive R-CHOP for 6 cycles. The primary endpoint is progression-free survival (time from randomization to progressive disease or death due to any cause). Secondary endpoints include complete response rate, overall response rate, overall survival, duration of response, quality of life, adverse events, clinical laboratory values, and PK parameters for duvelisib and its major metabolite. This study is open for enrollment. Clinical trial information: NCT02605694.
‘Living and dying well with end-stage liver disease’: Time for palliative care?
Authors: Pauline Kane, Philip Lodge, Katherine Hopkins, Lynda Greenslade, Adrian Tookman
Journal: Hepatology (2012)

We read with interest the article by Boyd etal., Living and dying well with end-stage liver disease: time for palliative care?1 We work closely with the liver unit at the Royal Free Hospital and are well aware of the lack of information available on the pharmacokinetics of opioids in liver disease and the challenges this presents. However, we read with some concern the statement that "Opioids can be problematic in a population with a high prevalence of substance abuse." Clearly there are anxieties (not least for the patient concerned) associated with prescribing opioids in this population but, regardless of a patient's previous history or the etiology of their underlying disease, it would be ethically wrong for this to result in poorly managed pain. Patients with end stage liver disease (ESLD) are a population where, historically, their pain was not acknowledged. With the added complication of a prevalent history of substance misuse resulting in a reluctance to prescribe opioids, this can mean that pain in this population is frequently poorly managed.2 These patients report an incidence of pain that is similar to that experienced in advanced colon and lung cancer,3 and we have a duty to provide good symptom control despite a previous history of opioid use. It can be very difficult to predict how patients with ESLD will respond to some medications, particularly opioids. Fear of causing an encephalopathy, particularly where a previous history exists, can result in a reluctance to prescribe opioids when they are needed. Regular and careful monitoring together with the use of short-acting opioids given at increased intervals means that a safe opioid regime can be prescribed. Although fentanyl is the opioid that appears to be the best tolerated in ESLD,5 there are practical difficulties in using it where pain is unstable and rapidly changing. Ideally, the use of a short-acting opioid is preferable but each patient should be monitored individually considering the many factors that affect the pharmacokinetics of these medications. This is a population where some have led lives where addictive behavior may have been prevalent, alienating family and friends, resulting in social isolation with very little support. It is imperative that these patients are supported along their disease trajectory with the emphasis being on each individual's needs and appropriate symptom management, regardless of their previous history, which is where palliative care can play a pivotal role.
The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.
Authors: Thierry Andre, Aimery De Gramont, Laurent Mineur, Jérôme Desramé, Roger Faroux, Jaafar Bennouna, Jérôme Dauba, Christophe Louvet, Simon Pernot, Olivier Jean Marie Dupuis, Yves Becouarn, May Mabro, Joëlle Egreteau, Olivier Bouche, Franck Bonnetain, Marine Hug de Larauze, Karine Le Malicot, Julien Taieb
Journal: Journal of Clinical Oncology (2016)

633 Background: The IDEA international collaboration was established to prospectively combine/analyze data from six randomized trials to assess whether a 3-month course of oxaliplatin/fluoropyrimidines-based adjuvant chemotherapy (CT) is non-inferior to the 6-month current standard treatment in stage III colon cancer (CC). The primary endpoint of IDEA was 3-year disease-free survival. The accrual goal for the French IDEA study was 2,000 patients. Methods: French IDEA randomized patients with stage III CC between 3 months (arm A) and 6 months (arm B) of adjuvant CT with modified (m) FOLFOX6 or XELOX (depending on physician/patient choice). Oxaliplatin was stopped in case of persistent neuropathy grade ≥2 with fluoropyrimidines continuation for the planned duration. Toxicity was graded during treatment and follow-up using NCI-CTCAE v3.0. Results: From May 2009 to May 2014, 2,023 patients were randomized in 129 French centers either to arm A (n=1009, 49.9%) or to arm B (n=1014, 50.1%). 2012 (99.5%) patients had stage III disease (N1: 75%; N2: 25%) and 11 patients had stage II (n=2) or stage IV disease (n=9). Median age was 64 years (18-85). 89.4% of patients received mFOLFOX6, 10.1% of patients received XELOX, and 0.5% of patients did not receive any study treatment. Overall, 94.1% and 77.5% of patients completed 3 months (arm A) and 6 months (arm B) of CT, respectively. Median oxaliplatin dose was 500 mg/m 2 in arm A and 747 mg/m 2 in arm B. Toxicity profiles depended on the FU backbone with more grade 3/4 neutropenia on mFOLFOX6 (15.0% vs 6.5%) and more grade 3/4 diarrhea (4.7% vs 8.1%) on XELOX. Grade 2/3-4 peripheral neuropathy was less common in arm A than in arm B (23.2/6% vs 37.9/20.4%). Grade 2/3-4 residual neuropathy for patients with a follow-up of at least 3 years (n=811, median follow-up of 3.91 years) was 2.3/0.5% in arm A vs 3.9/ 2.4% in arm B. At 6 months after randomization, mortality rate was 0.7% (n=7) on arm A and 0.5% (n=5) on arm B. Median follow-up is 2.74 years for the whole population. Conclusions: Both mFOLFOX6 and XELOX were safe. Peripheral neuropathy was lower in arm A than in arm B. Clinical trial information: 2009-010384-16.
Oral tolerance inhibits atopic dermatitis-like type 2 inflammation in mice by modulating immune microenvironments
Authors: J.O. Baek, J.Y. Roh, Y. Jung
Journal: Allergy (2016)

Oral tolerance is immune unresponsiveness induced by oral administration of innocuous antigens. Oral administration of allergens has been shown to be effective for suppressing IgE production in allergic responses. However, whether oral tolerance has a role in protection from allergic skin inflammation has not been fully investigated. Here, we evaluated the potential protective role of oral tolerance in a murine model of atopic dermatitis (AD) and investigated the underlying immunologic mechanisms.Mice were fed with ovalbumin (OVA) in drinking water then epicutaneously sensitized by repeated application of OVA to tape-stripped skin. Skin biopsies were analyzed for immunohistopathologic features. Levels of antibodies in sera and intestinal washes were measured by ELISA. Flow cytometry and real-time PCR analysis of the skin and mesenteric lymph nodes (MLN) were performed to investigate the immunologic effects of oral tolerance in epicutaneous (EC) sensitization-induced allergic responses.Induction of oral tolerance effectively inhibited inflammatory responses provoked by EC sensitization. Tolerogenic immune mediators were significantly increased in the skin and MLN of EC-sensitized mice following induction of oral tolerance. A marked increase in Il5 and Il13 expression and infiltration of eosinophils and type 2 innate lymphoid cells (ILC2) in the skin of EC-sensitized mice were significantly inhibited by oral tolerance.Oral tolerance plays a protective role in the development of AD in a murine model by modulating immune microenvironments to be more favorable for immune regulation. This modulation involves inhibition of ILC2 infiltration in skin lesions.
International Staging System (ISS) Is Superior to Durie-Salmon (DS) Staging in Predicting Overall Mortality in Multiple Myeloma (MM)
Authors: Sikander Ailawadhi, Taimur Sher, Mehul Patel, Lyudmyla Derby, Terry Mashtare, Gregory E. Wilding, Kena Miller, Alice Mohr, Kelvin Lee, Asher A. Chanan-Khan
Journal: Blood (2008)
Bleeding, transfusion and the risk of stroke after coronary surgery: A prospective cohort study of 2357 patients
Authors: Fausto Biancari, Tuomas Tauriainen, Andrea Perrotti, Magnus Dalén, Giuseppe Faggian, Ilaria Franzese, Sidney Chocron, Vito G. Ruggieri, Karl Bounader, Helmut Gulbins, Daniel Reichart, Peter Svenarud, Giuseppe Santarpino, Theodor Fischlein, Tamas Puski, Daniele Maselli, Carmelo Dominici, Saverio Nardella, Giovanni Mariscalco, Riccardo Gherli, Francesco Musumeci, Antonino S. Rubino, Carmelo Mignosa, Marisa De Feo, Ciro Bancone, Giuseppe Gatti, Luca Maschietto, Francesco Santini, Antonio Salsano, Francesco Nicolini, Tiziano Gherli, Marco Zanobini, Matteo Saccocci, Paola D'Errigo, Eeva-Maija Kinnunen, Francesco Onorati
Journal: International Journal of Surgery (2016)
The dexamethasone suppression test in acute grief
Authors: S R Shuchter, S Zisook, C Kirkorowicz, C Risch
Journal: American Journal of Psychiatry (1986)

Nineteen recently widowed women and men were given diagnostic interviews, psychometric evaluations, and dexamethasone suppression tests (DSTs). While 58% of the subjects (N = 11) met Research Diagnostic Criteria for depression, only 16% (N = 3) were nonsuppressors on the DST. In this population, nonsuppression was related more to levels of anxiety than to depression.
PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study
Authors: Ida Wong-Sefidan, Michelle Byrtek, Xiaolei Zhou, Jonathan W. Friedberg, Christopher Flowers, Brian K Link, Andrew D. Zelenetz, Keith L Dawson, Erin G. Reid
Journal: Blood (2013)
France’s air pollution causes 48 000 deaths a year
Authors: Anne Gulland
Journal: BMJ (2016)

Air pollution in France is responsible for 48 000 deaths a year, the country’s new public health agency has said.

Figures from Sante Publique France showed the effects of pollution from fine particles, mainly from vehicle exhausts.1 Researchers estimated levels of fine particulate matter in 36 219 communities in France and looked at the effect on life expectancy. The agency was created in April this year from a merger of France’s three national public health bodies focusing on public health surveillance, emergencies, and …
The emergency room as a clerkship site
Authors: G A Melchiode, D A Puryear, M Babick
Journal: American Journal of Psychiatry (1983)

The psychiatric emergency room of a county hospital is one of five clinical placement sites for the authors' medical school junior clerkship. The students assigned to the emergency room share the same core didactic work as students who are placed at more traditional sites, but the emergency room students have additional seminars in crisis intervention, aspects of emergency psychiatry, and orientation to social agencies. Analysis of data measuring the achievement of behavioral objectives common to all five clinical sites shows that emergency room students, in comparison with their peers at other sites, averaged more patient contact, more direct observation, and more supervisory experiences.
Costs of Contraceptive Coverage Under the Affordable Care Act—Reply
Authors: Mary C. Politi, Adam Sonfield, Tessa Madden
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identifying a therapeutic target for ablating new blood vessel formation in patients with asthma
Authors: Qi Ge, Janette Burgess, Anthony Ashton
Journal: European Respiratory Journal (2015)

Introduction: Angiogenesis is a feature of chronic asthma with the levels of multiple proangiogenic factors, including connective tissue growth factor (CTGF) and vascular growth factor (VEGF), increased in the lungs of patients with asthma. Preliminary data from our lab suggests that the proangiogenic effect of asthmatic airway smooth muscle cells is lost if CTGF is immunoprecipitated from the media but not restored by supplementation with recombinant CTGF. These data indicate that CTGF may be exerting these proangiogenic effects by binding to another protein. Aim: To identify other factor/s that bind to CTGF Methods: Plates were coated with CTGF C-terminal fragment (amino acids 253 to 350) (90 nM) then blocked with 1% BSA. The potential binding proteins were biotinylated and added to the CTGFcoated wells. The amount of protein bound to CTGF was detected using streptavidin conjugated HRP and TMB. Results: On dose response curves, angiopoietin (Ang)-1 (34±10 units (U)/nmol protein) and Slit3 (20±5 U/nmol protein) had the strongest association constants, with Von Willebrand factor, basic fibroblast growth factor and TNFα all having moderate affinity (range of 8-15 U/nmol protein) and VEGF-A165(5±4 U/nmol protein) and VEGF-D (3±0.7 U/nmol protein) showing low association/high disassociation kinetics. VEGF-A121, VEGF-C, Ang-2, PDGF-BB, TGF-β1, placenta growth factor, EGF, IL-1β, IL-17 and human chorionic gonadotropin had little or no binding to CTGF. Conclusion: Agents aimed at preventing blood vessel formation improve airway hyperresponsiveness and asthma symptoms. Identifying the binding partner for CTGF could help develop a new therapeutic approach for targeting asthma.